

# Imodium

TRADE MARK

loperamide hydrochloride

made to  
measure  
treatment for  
acute and  
chronic  
diarrhoea

*The tailored dosage means that  
patients only take Imodium when  
they need it with no interruption to normal routine.  
Imodium is easy to take and convenient to carry.*

*Designed for the specific control of  
diarrhoea, Imodium relieves pain and  
abdominal cramps rapidly and effectively.*

Imodium  
simply  
stops diarrhoea fast.

Further information is available from :



**Janssen Pharmaceutica**  
2340 Beerse, Belgium

or from :

Janssen Pharmaceutical Limited,  
Janssen House, Marlow, Bucks.

PL 0242/0028 PL 0242/0040

**WHY NOT SUBSCRIBE TO THE SPECIALIST JOURNALS PUBLISHED BY THE BMA:—A SELECTION INCLUDES**

Archives of Disease in Childhood, British Heart Journal, British Journal of Ophthalmology, Gut, Journal of Clinical Pathology & Journal of Neurology, Neurosurgery & Psychiatry.

FULL DETAILS OF SUBSCRIPTION RATES FROM BMA SPECIALIST PUBLICATIONS: BMA HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR  
TELEPHONE 01-387 4499 EXT. 309.



# Wake up to Surmontil say good-night to depression

Eighty-six per cent of depressives suffer from sleep disturbance.\* And since insomnia aggravates all the other symptoms, patients need help quickly. 'Surmontil' is the answer. When you promise your patient a good night's sleep, 'Surmontil' usually makes it come true. Immediately. And – at the same time – goes on working long-term against the major disorder. 'Surmontil' antidepressant – treatment of choice for sleep-disturbed depressives.

## Surmontil capsules

**TRIMIPRAMINE**  
for the sleep-disturbed, depressed patient.

\*Pollitt, *Proc. Roy. Soc. Med.*, 64, 1174-1178, 1971  
Further information in data sheet  
'Surmontil' is a trade mark.  
May & Baker Ltd. Dagenham Essex RM10 7XS



A member of  
the Rhône-Poulenc  
Group of Companies



**Dosage:** oral, nightly, 50-100 mg. Max. 300mg in severe cases. **Contraindications:** none known. **Precautions:** avoid acute recovery phase following myocardial infarction. Monitor liver function long-term. Supervise closely, patients with cardiovascular disorders as rare arrhythmias, sinus tachycardia with prolonged conduction times, myocardial infarction have been reported. Take care in patients with alcoholism, pre-existing hepatic disease, known epilepsy, existing brain damage or glaucoma. **Side effects:** (rare) vertigo, postural hypotension, tachycardia, dry mouth, accommodation difficulties, dysuria, gastro-intestinal upsets. Epileptiform seizures have occurred with excess 300mg daily.

# The new antirheumatic from Geigy



# VOLTAROL<sup>®</sup>

diclofenac sodium

## bridges the gap between efficacy and tolerability

**The potent antirheumatic effect  
and very good tolerability  
of Voltarol have been confirmed**

- in over 90 countries throughout the world
- in over 10,000,000 patients
- in comparison with aspirin, indomethacin, ibuprofen, ketoprofen, naproxen and phenylbutazone
- in more than 15,000 patients in controlled clinical trials.

**Presentation** Tablets containing 25mg diclofenac sodium, circular, slightly biconvex with bevelled edges, yellow enteric coated, approximately 7mm diameter, imprinted Geigy on one side.

**Mode of action** Voltarol is a non-steroidal agent with marked analgesic/anti-inflammatory and antipyretic properties. Like most other drugs in this class, it is an inhibitor of prostaglandin synthetase.

**Indications** Rheumatoid arthritis, osteoarthritis.

**Dosage** Oral: In adults the initial dosage is 25-50mg 3 times daily, depending on the severity of the condition. Maintenance dose should be reduced to the minimum amount that will provide continuous therapeutic control, usually 1 x 25mg tablet three times daily.

Dosage in children has not yet been established.

The tablets should be swallowed whole, with a meal.

**Contraindications** Peptic ulcer.

Voltarol is contraindicated in asthmatic patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory agents with prostaglandin synthetase inhibiting activity.

**Precautions** Voltarol should not be prescribed during pregnancy, unless there are compelling reasons for doing so.

Patients with a history of peptic ulcer, haematemesis, or melaena, or with severe hepatic or renal insufficiency, should be kept under close surveillance.

Voltarol has been reported to depress

salicylate levels, and vice versa; the clinical relevance of this phenomenon is not yet clear.

**Warnings & side-effects** Initially, some patients may complain of epigastric pain, nausea and diarrhoea, headache and slight dizziness. These side-effects are often transient, disappearing with continuation of medication.

Occasionally skin rash, peripheral oedema and abnormalities of serum transaminases have been reported.

Very rarely peptic ulcer and haematemesis or melaena have been reported, mainly in patients with a history of such disorders, or who were receiving concomitant anti-rheumatic medication.

**Accidental overdose** There is no known antidote to Voltarol and the treatment is

symptomatic. Immediate treatment consists of forced emesis to recover undigested tablets.

**Pharmaceutical precautions** Storage - protect from moisture.

**Legal Category** Prescription only.

**Package quantities** Basic N.H.S. prices  
Packs of 100. £9

**Further information** Pharmacodynamic studies have shown no potentiation of oral hypoglycaemic and anti-coagulant drugs.

**Product Licence No.** Tablets 25mg PL0001/0036

**Product Licence Holder** Geigy Pharmaceuticals, Macclesfield, Cheshire, SK10 2LY

